Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$2.70 - $14.23
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Latest price
Market Cap | $1.05B |
EV | $780.41M |
Shares Outstanding | 327.88M |
Beta | 1.04 |
Analyst Rating | BUY |
Analyst Target Price | $19.18 |
P/E 2025E | - |
P/Revenue 2025E | 2.31x |
Revenue | - |
EPS | 16.90% |
Operating Cash Flow | -15.70% |
Free Cash Flow | -11.10% |
Revenue | 84.50% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 45.23% |
Net Profit Margin 2025E | -56.41% |
ROE 2025E | -41.91% |
ROCE 2024 | -57.48% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Iovance Biotherapeutics, Inc.
IOVA
Sector
Healthcare
Industry
Biotechnology
CEO
Vogt, Frederick
Employees
838
Website
www.iovance.comIPO Date
2010-10-15
Headquarters
825 Industrial Road, Suite 400, San Carlos, California, 94070, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved